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T he recently published article by Oussalah et al reportsa retrospective analysis of a single-center cohort of 48
patients with luminal Crohn’s disease (CD) treated by com-
bined therapy with infliximab and azathioprine for at least
6 months and who then stopped azathioprine after a mean
of 30.2 months of combined therapy. The primary aim of
the study was to analyze predictive factors of infliximab
failure after azathioprine withdrawal. Infliximab failure was
defined either as a disease flare requiring shortening of the
dosing interval or increasing the infliximab dose to 10 mg/
kg, or switching to adalimumab, as acute or delayed hyper-
sensitivity reactions leading to infliximab discontinuation,
or as CD-related surgery. The survival probabilities without
infliximab failure were 85% (65%) at 12 months and 41%
(618%) at both 24 and 32 months. Independent predictive
factors of infliximab failures were combined therapy expo-
sure <811 days, C-reactive protein (CRP) >5 mg/L, and
platelet counts >298 109/L.
COMMENTS
Although the study by Oussalah et al is retrospective
and relatively small-sized, it tackles a very important and
relevant question. After publication of the results of the
SONIC trial, combination therapy with antitumor necrosis
factor (TNF) and immunosuppressant has been recognized
as the most efficacious option to treat early severe immu-
nosuppressant-naı¨ve CD patients.1 Although evidence to do
the same in patients having failed immunosuppressant is
lacking, it has also become a broadly used treatment
option in this setting. However, most patients and physi-
cians are concerned about safety issues, mainly the risk of
opportunistic infections and lymphoma, which could
appear with such long-term treatment. Therefore, solutions
for treatment deescalation are currently explored in pro-
spective and retrospective studies. In the previously pub-
lished controlled trial comparing immunosuppressant with-
drawal after 6 months of combined therapy with infliximab
to continued combined therapy, no significant difference in
infliximab failure was found between the two groups over
a follow-up of 2 years.2 However, CRP concentrations
were significantly higher and infliximab trough levels sig-
nificantly lower in patients having withdrawn azathioprine.
As these features have been associated with an increased
risk of treatment failure, a doubt remains about the long-
term sustained benefit with infliximab monotherapy. In the
present study, Oussalah et al found a relapse rate after aza-
thioprine withdrawal very similar to the one found in the
IMID study with or without azathioprine withdrawal.2,3
Interestingly, they could identify predictive factors of
relapse: essentially shorter duration of combined therapy
and persistent signs of inflammation, i.e., elevated CRP
and platelet counts. Biological signs of inflammation have
already been associated with the risk of relapse after aza-
thioprine withdrawal in a different clinical setting.4 The li-
mitation of the present study is that there is no proof that
these factors are really predictive of relapse after azathio-
prine cessation or more broadly predictive of relapse under
infliximab treatment. Indeed, as there is currently no proof
of an excess of relapse when withdrawing azathioprine
beyond 6 months of combined therapy, the relapse may
have occurred in the same patients even if combined ther-
apy had been continued. Particularly, persistent signs of
inflammation are a nonspecific marker for higher risk of
relapse in CD and, interestingly, it is not the duration
of azathioprine therapy that was associated with a risk of
relapse but rather the duration of infliximab therapy (the
duration of combined therapy in the present study was
most probably equivalent to a duration of infliximab ther-
apy, as only 2/48 patients started azathioprine after inflixi-
mab). Yet, globally patients having been in stable remis-
sion over long-term infliximab are probably at low risk of
relapse because they are responding particularly well to
this drug and probably less prone to develop immunization
against the drug. In other words, this study does not permit
conclusions about the optimal duration of combined ther-
apy and in particular does not demonstrate that one should
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wait for at least 27 months before stopping azathioprine. It
also does not show that stopping azathioprine in patients
with elevated CRP or platelet count increases their risk of
relapse.
Therefore, although this study confirms that patients
in stable remission after prolonged combined treatment
with infliximab and azathioprine and having a low level
of systemic inflammation have a low risk of relapse, it
leaves us with an unresolved question as to whether we
should use combined therapy for more than 6 months, and
even whether we should use it in place of anti-TNF
monotherapy in case of immunosuppressant failure. Ulti-
mately, a firm response to this important question would
require a properly designed prospective controlled trial.
Edouard Louis, MD, PhD
Department of Gastroenterology, CHU Lie`ge, Belgium
REFERENCES
1. Colombel JF, Sandborn WJ, Reinisch W, et al. Infliximab, azathioprine,
or combination therapy for Crohn’s disease. N Engl J Med. 2010;362:
1383–1395.
2. Van Assche G, Magdelaine-Beuzelin C, D’Haens G, et al. Withdrawal
of immunosuppression in Crohn’s disease treated with scheduled inflixi-
mab maintenance: a randomized trial. Gastroenterology. 2008;134:
1861–1868.
3. Oussalah A, Chevaux J-B, Fay R, et al. Predictors of infliximab failure
after azathioprine withdrawal in Crohn’s disease treated with combina-
tion therapy. Am J Gastroenterol. 2010;105:1142–1149.
4. Treton X, Bouhnik Y, Mary J-Y, et al. Azathioprine withdrawal in
patients with Crohn’s disease maintained on prolonged remission: a
high risk of relapse. Clin Gastroenterol Hepatol. 2009;7:80–85.
J_ID: IBD Customer A_ID: 10-0383 Cadmus Art: IBD21407 Date: 17-June-10 Stage: Page: 2
ID: subramaniank I Black Lining: [ON] I Time: 13:26 I Path: N:/3b2/IBD#/Vol00000/100202/APPFile/C2IBD#100202
Inflamm Bowel DisLouis
2
